Triple-negative breast cancer (TNBC) accounts for 15–20% of breast cancers, which is characterized by a lack of over-expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) (Hudis and Gianni 2011). Here, ERBB2 is linked to triple-negative breast carcinoma.